Background Selecting the appropriate treatment for breast cancer requires accurately determining the estrogen receptor (ER) status of the tumor. However, the standard for determining this status, immunohistochemical analysis of formalin-fixed paraffin embedded samples, suffers from numerous technical and reproducibility issues. Assessment of ER-status based on RNA expression can provide more objective, quantitative and reproducible test results. Methods To learn a parsimonious RNA-based classifier of hormone receptor status, we applied a machine learning tool to a training dataset of gene expression microarray data obtained from 176 frozen breast tumors, whose ER-status was determined by applying ASCO-CAP guidelines to standardized immunohistochemical testing of formalin fixed tumor. Results This produced a three-gene classifier that can predict the ER-status of a novel tumor, with a cross-validation accuracy of 93.17±2.44%. When applied to an independent validation set and to four other public databases, some on different platforms, this classifier obtained over 90% accuracy in each. In addition, we found that this prediction rule separated the patients' recurrence-free survival curves with a hazard ratio lower than the one based on the IHC analysis of ER-status. Conclusions Our efficient and parsimonious classifier lends itself to high throughput, highly accurate and low-cost RNA-based assessments of ER-status, suitable for routine high-throughput clinical use. This analytic method provides a proof-of-principle that may be applicable to developing effective RNA-based tests for other biomarkers and conditions.
References
[1]
Davies C, Godwin J, Gray R, Clarke M, Cutter D, et al. (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378: 771–784.
[2]
Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, et al. (2010) American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28: 2784–2795.
[3]
Cameron MA (2009) Commission of inquiry on hormone receptor testing. St. John's NL: Government of Newfoundland and Labrador.
[4]
Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, et al. (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100: 8418–8423.
[5]
Paik S (2006) Molecular profiling of breast cancer. Curr Opin Obstet Gynecol 18: 59–63.
[6]
Gruvberger S, Ringner M, Chen Y, Panavally S, Saal LH, et al. (2001) Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 61: 5979–5984.
[7]
van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530–536.
[8]
Germain DR, Graham K, Glubrecht DD, Hugh JC, Mackey JR, et al. (2011) DEAD box 1: a novel and independent prognostic marker for early recurrence in breast cancer. Breast Cancer Res Treat 127: 53–63.
[9]
Harrell JC, Prat A, Parker JS, Fan C, He X, et al. (2012) Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse. Breast Cancer Res Treat 132: 523–535.
[10]
Edgar R, Domrachev M, Lash AE (2002) Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30: 207–210.
[11]
Takahashi S, Moriya T, Ishida T, Shibata H, Sasano H, et al. (2008) Prediction of breast cancer prognosis by gene expression profile of TP53 status. Cancer Sci 99: 324–332.
[12]
Li Y, Zou L, Li Q, Haibe-Kains B, Tian R, et al. (2010) Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat Med 16: 214–218.
[13]
Sabatier R, Finetti P, Adelaide J, Guille A, Borg JP, et al. (2011) Down-regulation of ECRG4, a candidate tumor suppressor gene, in human breast cancer. PLoS One 6: e27656.
[14]
Cheadle C, Vawter MP, Freed WJ, Becker KG (2003) Analysis of microarray data using Z score transformation. J Mol Diagn 5: 73–81.
[15]
Cover TM (2006) Elements of information theory. Hoboken, N.J: Wiley-Interscience. 748 p.
[16]
Peng H, Long F, Ding C (2005) Feature selection based on mutual information: criteria of max-dependency, max-relevance, and min-redundancy. IEEE Trans Pattern Anal Mach Intell 27: 1226–1238.
[17]
Herbrich R (2002) Learning kernel classifiers: theory and algorithms. Cambridge, Mass: MIT Press. 364 p.
[18]
Witten IH, Frank E, Hall MA (2011) Data mining : practical machine learning tools and techniques Burlington, MA: Morgan Kaufmann. 629 p.
[19]
Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719–748.
[20]
Stabach PR, Thiyagarajan MM, Weigel RJ (2005) Expression of ZER6 in ERalpha-positive breast cancer. J Surg Res 126: : 86–91; discussion 81–82.
[21]
Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ (1990) Basic local alignment search tool. J Mol Biol 215: 403–410.
[22]
Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, et al. (2008) Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 14: 518–527.
[23]
Gong Y, Symmans WF, Pusztai L (2007) Gene-expression microarrays provide new prognostic and predictive tests for breast cancer. Pharmacogenomics 8: 1359–1368.
[24]
Gong Y, Yan K, Lin F, Anderson K, Sotiriou C, et al. (2007) Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. Lancet Oncol 8: 203–211.
[25]
Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, et al. (2009) An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat 123: 725–731.
[26]
Hu Z, Fan C, Oh DS, Marron JS, He X, et al. (2006) The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 7: 96.
[27]
Huang E, Cheng SH, Dressman H, Pittman J, Tsou MH, et al. (2003) Gene expression predictors of breast cancer outcomes. Lancet 361: 1590–1596.
[28]
Huang E, West M, Nevins JR (2003) Gene expression profiling for prediction of clinical characteristics of breast cancer. Recent Prog Horm Res 58: 55–73.
[29]
Kun Y, How LC, Hoon TP, Bajic VB, Lam TS, et al. (2003) Classifying the estrogen receptor status of breast cancers by expression profiles reveals a poor prognosis subpopulation exhibiting high expression of the ERBB2 receptor. Hum Mol Genet 12: 3245–3258.
[30]
Oh DS, Troester MA, Usary J, Hu Z, He X, et al. (2006) Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol 24: 1656–1664.
[31]
Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747–752.
[32]
Slamon DJ (1987) Proto-oncogenes and human cancers. N Engl J Med 317: 955–957.
[33]
Smid M, Wang Y, Klijn JG, Sieuwerts AM, Zhang Y, et al. (2006) Genes associated with breast cancer metastatic to bone. J Clin Oncol 24: 2261–2267.
[34]
Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98: 10869–10874.
[35]
Tibshirani R, Hastie T, Narasimhan B, Chu G (2002) Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A 99: 6567–6572.
[36]
Tusher VG, Tibshirani R, Chu G (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 98: 5116–5121.
[37]
Usary J, Llaca V, Karaca G, Presswala S, Karaca M, et al. (2004) Mutation of GATA3 in human breast tumors. Oncogene 23: 7669–7678.
[38]
Mehra R, Varambally S, Ding L, Shen R, Sabel MS, et al. (2005) Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis. Cancer Res 65: 11259–11264.
[39]
Jumppanen M, Gruvberger-Saal S, Kauraniemi P, Tanner M, Bendahl PO, et al. (2007) Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers. Breast Cancer Res 9: R16.
[40]
Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, et al. (2003) Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 100: 10393–10398.
[41]
Paik S, Tang G, Shak S, Kim C, Baker J, et al. (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24: 3726–3734.
[42]
Stretch C, Khan S, Asgarian N, Eisner R, Vaisipour S, et al. (2013) Effects of sample size on differential gene expression, rank order and prediction accuracy of a gene signature. PLoS One 8: e65380.
[43]
Ein-Dor L, Kela I, Getz G, Givol D, Domany E (2005) Outcome signature genes in breast cancer: is there a unique set? Bioinformatics 21: 171–178.
[44]
West M, Blanchette C, Dressman H, Huang E, Ishida S, et al. (2001) Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci U S A 98: 11462–11467.
